Cancer treatment decisions may involve several specialists, multiple test results and more than one reasonable option. A cancer second opinion allows another qualified oncology team to review the diagnosis, stage, medical records and proposed treatment plan before the patient makes a major decision.
A second opinion may confirm the original recommendation. It may also identify missing information, suggest a pathology or radiology review, recommend additional biomarker testing, change the order of treatment or offer another medically appropriate option. It does not guarantee that the diagnosis or treatment will change.
For international patients considering a cancer second opinion in Turkey, the quality of the review depends heavily on the completeness and organisation of the medical file. Sending only a short diagnosis, a photograph of one report or a list of symptoms is rarely enough for a meaningful oncology assessment.
This guide explains when a second opinion may be useful, which medical records to send, how pathology and imaging are reviewed, when an online assessment may be sufficient and when an in-person examination or additional testing may still be required.
A cancer second opinion is an independent review by a doctor or multidisciplinary team that was not responsible for the original recommendation. The reviewing specialist studies the available evidence and considers whether the diagnosis, stage and proposed treatment are consistent with the clinical findings.
Depending on the case, the review may involve:
• a medical oncologist;
• a surgical oncologist or organ-specific cancer surgeon;
• a radiation oncologist;
• a pathologist with experience in the relevant tumour type;
• a radiologist or nuclear medicine specialist;
• a medical geneticist or molecular tumour specialist;
• other specialists whose expertise is relevant to the diagnosis.
The second team may agree with the original plan. Confirmation can still be valuable because it gives the patient greater confidence that the diagnosis and treatment strategy have been reviewed independently.
A well-prepared review can often address questions such as:
• Does the available pathology support the stated cancer diagnosis and subtype;
• Is the documented stage consistent with the imaging and other findings;
• Is the proposed treatment appropriate for this diagnosis and stage;
• Should surgery, systemic treatment or radiotherapy come first;
• Are relevant biomarker or molecular tests missing;
• Are there reasonable alternatives that should be discussed;
• Is a pathology, radiology or multidisciplinary tumour board review advisable;
• Which additional examinations may be needed before a final decision;
• Can part of the treatment or follow-up be continued in the patient’s home country.
A remote second opinion has limits. A specialist may be unable to make a final recommendation when the records are incomplete, the pathology is uncertain, the imaging is outdated, the patient’s condition has changed or a physical examination is necessary.
The review should not be presented as a guaranteed diagnosis, guaranteed treatment or promise of a particular outcome. Final decisions remain the responsibility of the licensed physicians and medical institutions caring for the patient.
A second opinion may be particularly useful before an irreversible or high-impact decision. Examples include major surgery, combined treatment, a change from curative to palliative intent, treatment after recurrence or a recommendation based on uncertain pathology.
Patients may also consider another review when:
• the cancer is rare or has an unusual subtype;
• the pathology report is unclear or does not match the clinical picture;
• different doctors have proposed substantially different plans;
• the stage is uncertain;
• the disease has progressed despite treatment;
• the cancer has returned after a period of remission;
• surgery has been described as impossible or exceptionally risky;
• extensive surgery has been recommended and organ-preserving options need evaluation;
• biomarker testing is incomplete;
• a molecular alteration has been found but its treatment relevance is unclear;
• immunotherapy or targeted therapy is being considered;
• treatment caused serious toxicity and another approach is needed;
• the patient wants to understand all reasonable options before travelling abroad.
Seeking another opinion does not mean that the first doctor made an error. Oncology often involves several acceptable strategies, and specialists may weigh benefits, risks, timing and available evidence differently.
Some cancers and complications require prompt treatment. A patient should ask the treating oncologist whether waiting for another review could create a medical risk.
A planned international consultation should never delay emergency assessment for symptoms such as severe shortness of breath, uncontrolled bleeding, new weakness or paralysis, confusion, seizures, high fever during cancer treatment, severe dehydration or rapidly worsening pain.
If the patient is medically unstable, immediate care should be obtained locally. A second opinion can be organised after the urgent problem has been assessed and stabilised.
The effect of a second opinion varies. The new team may confirm the diagnosis and plan without recommending any change. In other cases, the review may affect one or more parts of the treatment pathway.
Pathology review may refine the tumour type, grade or subtype. This can be important in rare cancers, sarcomas, lymphomas, brain tumours and cancers with overlapping microscopic features.
A revised classification may lead the team to request different molecular tests or consider a different treatment protocol. Any proposed change should be based on direct review of the relevant pathology material and supporting clinical information.
The reviewing team may interpret the extent of disease differently after examining the original CT, MRI or PET-CT images. It may also identify that newer imaging is required because the available studies no longer reflect the current condition.
Changes in staging can influence whether treatment is intended to remove or control a local tumour, reduce the risk of recurrence or treat disease that has spread to other organs.
The same treatments may remain appropriate, but the recommended order can change. For example, a team may consider systemic treatment before surgery, surgery before adjuvant therapy, radiotherapy before or after another treatment, or a period of observation in carefully selected situations.
The correct sequence depends on the cancer type, stage, symptoms, treatment objective and the patient’s general health.
Another team may suggest a different operation, radiotherapy technique, drug combination or local treatment. It may also conclude that an option discussed online is not supported by the diagnosis or available evidence.
A different recommendation is not automatically better. The doctors should explain the expected benefit, important risks, alternatives and strength of evidence for each option.
Pathology and molecular results may show that further testing is relevant. Depending on the cancer, this may include immunohistochemistry, hereditary cancer assessment, PD-L1, MSI or MMR testing, HER2 testing, BRCA analysis or broader next-generation sequencing.
Not every patient needs every test. Testing should be selected because the result could help confirm the diagnosis, clarify prognosis, identify an approved treatment or support another clinically relevant decision.
In advanced cancer, the review may include pain control, nutritional support, management of treatment side effects and other palliative-care measures. Supportive care can be provided alongside active cancer treatment and should not be interpreted as abandonment of care.
The reviewing team should receive a structured file that explains what has happened from diagnosis to the present. The exact requirements depend on the tumour and the question being asked, but the following records are commonly useful.
Begin with a concise chronological summary. It should include:
• the patient’s age and current country of residence;
• the confirmed or suspected diagnosis;
• the date and method of diagnosis;
• the known stage;
• the main sites of disease;
• previous operations and cancer treatments;
• the response to treatment;
• current symptoms and general condition;
• the current doctor’s recommendation;
• the main questions for the second-opinion team.
The summary helps the coordinator and doctor understand the case quickly. It does not replace the original reports.
Send the final pathology report from every relevant biopsy or operation. The report may describe the tumour type, grade, margins, lymph nodes, immunohistochemistry and other findings used to establish the diagnosis.
If there were several biopsies or surgeries, include each report with its date. Preliminary reports should be followed by the final signed version when available.
For some cases, reading the written report is not enough. The reviewing pathologist may need the original glass slides, unstained slides, paraffin block or a validated digital pathology image.
These materials remain stored by the pathology laboratory or hospital where the biopsy or surgery was performed. The patient may need to sign a release form, and the receiving centre should provide exact packaging, labelling and courier instructions before anything is shipped.
Do not send irreplaceable pathology material without confirming the receiving laboratory, required material and return process.
Send the written reports and the original images for relevant examinations, including:
• CT;
• MRI;
• PET-CT;
• mammography;
• ultrasound;
• bone scan;
• other diagnosis-specific imaging.
Screenshots, photographs of a computer screen and selected JPEG images are usually inadequate for a formal radiology review. The original images should preferably be provided in DICOM format through a secure upload link, hospital portal, encrypted digital medium or another method accepted by the receiving institution.
Each study should be labelled with the examination date and body region. If more than one study exists, send the earlier and latest examinations so the team can assess change over time.
Include recent blood tests and other results relevant to diagnosis, treatment safety and organ function. These may include:
• complete blood count;
• liver and kidney function;
• electrolytes;
• tumour markers when clinically relevant;
• hormone tests;
• bone marrow reports;
• endoscopy or bronchoscopy reports;
• cardiac or pulmonary assessments required for treatment planning.
Older results may still provide useful history, but the reviewing team may request current tests before making a final recommendation.
If the patient has had surgery, send the full operative report rather than only the name of the procedure. The report may describe what the surgeon found, which tissues were removed, whether the procedure was complete and whether complications occurred.
Hospital discharge summaries should also be included because they document the inpatient course, complications, medications and follow-up instructions.
For chemotherapy, immunotherapy, targeted therapy or hormone therapy, provide:
• medication names;
• doses when available;
• treatment dates;
• number of cycles;
• dose reductions or interruptions;
• response assessments;
• important side effects;
• reason the treatment ended or changed.
The trade name alone may not be sufficient because the same medicine can be used in different combinations and schedules.
Provide the radiotherapy summary, including the treated area, total dose, number of fractions and treatment dates. If the new team is considering additional radiotherapy, it may also request the original treatment plan, dose distribution and related imaging.
Send complete reports for any testing already performed, such as:
• immunohistochemistry;
• PD-L1;
• MSI or MMR;
• HER2;
• hormone receptors;
• BRCA1 and BRCA2;
• EGFR, ALK, ROS1, BRAF, MET, RET or NTRK;
• next-generation sequencing;
• hereditary cancer testing.
Include the complete laboratory report rather than a short message saying that a result was positive or negative. The reviewing doctor may need the testing method, specimen date, tumour content, detected alteration and laboratory interpretation.
Prepare a current list of prescription medicines, over-the-counter medicines and supplements. Include doses when known.
Also report:
• medication allergies;
• heart, lung, kidney or liver disease;
• diabetes;
• autoimmune conditions;
• active or recent infections;
• previous organ transplantation;
• pregnancy or plans for pregnancy when relevant;
• implanted medical devices;
• previous severe treatment reactions.
This information can affect treatment safety and suitability.
Send the written plan from the treating team whenever possible. It should state the proposed treatment, treatment objective and expected sequence.
If the recommendation was only explained verbally, ask the doctor for a consultation note or written summary. The second-opinion team cannot meaningfully compare two plans if it does not know what the first team recommended and why.
Clear organisation can reduce avoidable questions and delays. Use separate folders for pathology, imaging reports, DICOM images, laboratory results, operations, systemic therapy, radiotherapy and molecular testing.
File names should include the date, record type and institution. For example:
• 2026-08-14_Pathology_Report_Hospital_Name.pdf;
• 2026-09-02_PET-CT_Report_Imaging_Centre.pdf;
• 2026-09-02_PET-CT_DICOM;
• 2026-10-20_Chemotherapy_Summary.pdf.
Use the international date format year-month-day to keep records in chronological order. Remove obvious duplicate files, but keep all clinically relevant versions and addenda.
Avoid sending hundreds of unrelated photographs through separate messages. Ask for the secure transfer method, accepted file types and maximum upload size before sending sensitive health information.
English records are usually easiest for an international review. If documents are in another language, ask whether professional translation is required before paying for a full translation.
In some cases, the coordinator can identify which key reports need translation first. The original document should always be retained and provided together with the translated version.
Machine translation may help a coordinator understand the subject of a document, but important pathology, operative and treatment records may require a qualified medical translation for clinical use.
Pathology is the foundation of many cancer treatment decisions. A specialist pathology review may be considered when the cancer is rare, the wording is uncertain, the clinical behaviour is unusual or the planned treatment depends on a precise subtype or biomarker.
The reviewing laboratory may:
• examine the original slides;
• prepare new sections from a paraffin block;
• repeat selected immunohistochemical stains;
• request additional molecular testing;
• compare several specimens obtained at different times.
Additional testing should be explained and approved before it is performed. The patient should also ask how much tissue will be used, whether enough material will remain for future tests and how the block or slides will be returned.
A radiology second opinion involves direct examination of the original images, not only the written report. The radiologist may reassess the primary tumour, lymph nodes, distant lesions, treatment response and whether a finding requires further investigation.
The radiology review should be interpreted together with pathology, symptoms, previous treatment and the timing of the scan. Imaging alone does not establish every cancer diagnosis.
If the scan quality is inadequate or the disease may have changed, the team may recommend repeat imaging in Turkey or in the patient’s home country.
Complex cases may benefit from discussion by a multidisciplinary tumour board. Participants can include medical oncology, surgery, radiation oncology, radiology, pathology, nuclear medicine, genetics and supportive-care specialists.
A tumour board is most useful when the key records are available before the meeting. Its recommendation should identify the clinical question, the evidence reviewed and the proposed next step.
Not every routine case needs a full tumour board. The reviewing oncologist should determine whether multidisciplinary discussion could materially improve the decision.
Many international second-opinion requests can begin with remote document screening. The initial review may establish whether the file is sufficient, which specialist is appropriate and whether travel is likely to add value.
Depending on the case, remote review may include:
• review of written medical records;
• preliminary review of DICOM imaging;
• review of existing pathology and molecular reports;
• identification of missing documents or tests;
• an online consultation with the relevant specialist;
• a provisional written assessment;
• an estimate of the examinations or treatment that may be needed in Turkey.
Travel may be necessary when the specialist needs:
• a physical or neurological examination;
• new imaging or laboratory tests;
• a fresh biopsy;
• direct pathology testing that cannot be completed remotely;
• assessment by several specialists;
• urgent symptom management;
• treatment that cannot safely be delayed.
The initial remote assessment should not be described as a final treatment plan when important clinical information is still missing.
The exact process varies by medical centre, but a structured international review generally follows several stages.
The patient sends the available records and main questions. A coordinator checks whether the essential pathology, imaging and treatment information is present and requests missing items.
The case should be matched to a doctor with experience in the relevant cancer type and treatment decision. The hospital brand alone does not determine whether a specialist is suitable for a particular case.
The specialist evaluates the available records. The doctor may request direct radiology or pathology review, additional tests or input from another discipline.
Complex decisions may be reviewed by a tumour board or a smaller group of relevant specialists. The purpose is to integrate different areas of expertise into one recommendation.
The patient should receive a clear explanation of:
• whether the diagnosis and stage can be confirmed from the available evidence;
• which information remains uncertain;
• whether the current treatment plan is supported;
• which alternatives may be reasonable;
• what additional examinations are recommended;
• whether an in-person visit is required;
• what the next practical step should be.
If the patient decides to continue in Turkey, the responsible medical team confirms the plan after any necessary examination or testing. The written proposal should explain the anticipated schedule, important risks, expected hospital stay, follow-up arrangements and estimated costs.
There is no single reliable turnaround time for every case. Timing depends on the completeness of the file, specialist availability, need for translation, volume of imaging, pathology shipment, additional staining, molecular testing and tumour board scheduling.
A coordinator may acknowledge receipt quickly, but that is not the same as a completed medical opinion. Patients should ask when the medical review is expected to begin and what event could extend the timeline.
Urgency should be communicated clearly. The patient should also ask the current oncologist whether treatment can safely wait for the review.
The total cost may depend on:
• the number and specialties of doctors involved;
• online consultation or in-person assessment;
• radiology re-interpretation;
• pathology review;
• additional immunohistochemistry;
• molecular or genetic testing;
• translation of medical records;
• courier shipment of pathology material;
• new imaging or laboratory examinations;
• multidisciplinary tumour board review;
• preparation of a written medical report.
The patient should request a written estimate that distinguishes the specialist consultation from optional or conditionally required tests. A low initial price may not represent the full evaluation needed for a clinically useful opinion.
A second opinion does not automatically require repeating every test. Existing results may be sufficient when they are recent, complete, technically adequate and available in the correct format.
Repeat testing may be recommended when:
• the original study is too old for the current decision;
• the image quality is inadequate;
• only a written report is available without the original images;
• pathology material is insufficient or results conflict;
• the tumour may have changed after treatment;
• the biomarker method does not answer the current clinical question;
• the patient has developed new symptoms;
• the result could materially change treatment.
The medical team should explain why a repeated or additional test is necessary and how the result may affect the plan.
Patients should avoid purchasing non-refundable flights before the medical centre has screened the records and confirmed whether an in-person visit is useful.
Before travelling, clarify:
• which original records, discs, slides or blocks must be carried;
• which specialists will evaluate the case;
• which tests are provisionally planned;
• how many days may be required;
• whether the patient is medically fit to fly;
• whether a companion is advisable;
• what the estimated costs include;
• how urgent complications would be managed;
• how follow-up will continue after returning home.
Patients who are acutely unwell should obtain local medical advice before flying.
Patients should be cautious if a provider:
• guarantees that the diagnosis or treatment plan will change;
• promises a cure or a particular medical result;
• recommends travel before basic records have been screened;
• selects treatment before pathology and stage are sufficiently documented;
• quotes a complete treatment package without medical assessment;
• discourages communication with the patient’s current oncologist;
• cannot identify the doctor or team reviewing the case;
• provides no written explanation of the recommendation.
A responsible service should explain what has been reviewed, what remains uncertain and which decisions require an in-person assessment.
A useful written assessment should be specific enough to share with the treating team. It may include:
• the records and dates reviewed;
• the diagnosis and stage that can be supported;
• areas of uncertainty;
• the treatment objective;
• the recommended treatment or options;
• the reason for the recommendation;
• important alternatives;
• tests needed before treatment;
• safety considerations;
• a proposed sequence and follow-up plan;
• whether another specialist or tumour board should review the case.
The document should clearly distinguish a provisional records-based opinion from a final recommendation made after physical examination and additional testing.
Different recommendations can be difficult to interpret. Ask each team to explain:
• which diagnosis and stage it is using;
• which records it reviewed;
• the objective of treatment;
• the expected benefit and main risks;
• the evidence or guideline supporting the recommendation;
• why the alternative plan was not preferred;
• whether the case should be discussed directly between the doctors.
Sometimes the difference comes from missing information rather than genuine disagreement. A pathology review, updated scan or joint discussion may resolve the issue.
The patient should not combine parts of two incompatible plans without medical supervision.
1. Can you confirm the diagnosis and stage from the records provided;
2. Do you need the original pathology slides or paraffin block;
3. Have you reviewed the original imaging or only the written report;
4. Is the current treatment objective curative, disease-controlling or symptom-focused;
5. Do you agree with the proposed treatment and its sequence;
6. Which alternatives are medically reasonable;
7. Are any biomarker or molecular tests missing;
8. Could another treatment be more appropriate before surgery or radiotherapy;
9. Which part of your opinion is provisional;
10. Which tests would need to be repeated in Turkey and why;
11. Can treatment continue in my home country;
12. What symptoms require urgent medical attention;
13. How should the new recommendation be discussed with my current oncology team;
14. What costs are included in the proposed review or treatment plan;
15. Who will coordinate follow-up after I return home.
Recmed Medical Travel coordinates international medical travel and specialist access. Recmed does not diagnose cancer, prescribe treatment or replace the patient’s treating oncology team.
Depending on the case, coordination may include:
1. reviewing the medical file for completeness;
2. preparing a chronological case summary;
3. identifying an oncologist, surgeon or other specialist whose expertise matches the diagnosis;
4. coordinating secure transfer of reports and DICOM imaging;
5. arranging pathology or radiology review when requested by the medical team;
6. organising an online or in-person consultation;
7. coordinating multidisciplinary review when clinically appropriate;
8. obtaining a written medical proposal and estimated costs;
9. arranging appointments, airport transfers, accommodation guidance and interpretation;
10. helping transfer discharge records and follow-up recommendations to the patient and local doctor.
All medical conclusions and treatment decisions are made by licensed doctors and authorised healthcare institutions.
Before requesting a cancer second opinion in Turkey, prepare:
• a one-page chronological medical summary;
• final pathology reports;
• information about available slides and paraffin blocks;
• imaging reports;
• original CT, MRI or PET-CT images in DICOM format;
• recent laboratory results;
• operation reports and discharge summaries;
• chemotherapy, immunotherapy, targeted-therapy or hormone-therapy records;
• radiotherapy summary and dates;
• biomarker, molecular and genetic test reports;
• current medications and allergies;
• relevant medical conditions;
• the existing written treatment recommendation;
• a list of the patient’s main questions.
The coordinator can advise which materials are essential for the first screening and which may be requested later.
No. Second opinions are a recognised part of medical decision-making, especially when the diagnosis is rare, the treatment has major consequences or several reasonable options exist. The second team may confirm the original recommendation.
Often, an initial review can begin remotely if complete records and imaging are available. A physical examination, pathology testing, repeat imaging or other examinations may still be required before a final treatment recommendation.
No. It may confirm the existing plan, recommend additional testing, refine the diagnosis or suggest another approach. No responsible coordinator or doctor should promise that the plan will change.
Not always. The report is essential, but direct review of slides, a paraffin block or digital pathology may be required when the diagnosis is uncertain or the treatment depends on a precise tumour classification.
Usually not. A radiologist generally needs the original DICOM images to perform an independent review. The written report should be sent with the images.
Ask the receiving team which documents require professional translation. Keep the original files and send them with any translated versions. Important pathology, operative and treatment records may require qualified medical translation.
Do not stop, delay or change treatment without speaking to the responsible oncologist. Ask whether there is enough time to wait safely for another review.
A second opinion does not automatically transfer responsibility for treatment. If the patient wants to continue with the new team, the doctors and hospital must confirm acceptance, scheduling and the final treatment plan.
In many cases, all or part of treatment can continue locally if the required medicine, monitoring and specialist support are available. The Turkish and local medical teams should agree on the protocol, follow-up schedule and management of complications.
A family member may help collect documents and coordinate communication, but the patient’s consent and identity verification may be required before sensitive medical information is reviewed or shared.
No. Recmed coordinates access to medical review and care. Only the responsible medical specialists can determine whether another treatment is appropriate, and no ethical provider can guarantee a particular cancer outcome.
Patients considering an oncology second opinion in Turkey can send their available medical records to Recmed Medical Travel for initial file screening and coordination with an appropriate specialist.
The first objective is to determine:
• whether the diagnosis and stage are sufficiently documented;
• whether pathology or imaging should be reviewed directly;
• whether important test results are missing;
• which specialist or multidisciplinary team should evaluate the case;
• whether the first assessment can begin remotely;
• whether travelling to Turkey is likely to add value;
• which examinations may be needed before a final plan;
• what the proposed review or treatment estimate includes.
A complete and organised medical file allows the oncology team to provide a more focused assessment and reduces avoidable delays.
This article is provided for general educational purposes and does not constitute medical advice, diagnosis or a treatment recommendation.
The need for a second opinion, urgency of treatment, choice of tests and final treatment plan must be determined by licensed physicians after reviewing the patient’s complete medical information. Do not begin, stop or change cancer treatment solely on the basis of online information.
If symptoms are severe, rapidly worsening or potentially life-threatening, seek urgent medical care at the patient’s current location rather than waiting for an international consultation or travel.
• National Cancer Institute – Definition of Second Opinion https://www.cancer.gov/publications/dictionaries/cancer-terms/def/second-opinion
• National Cancer Institute – Finding Cancer Care and Getting a Second Opinion https://www.cancer.gov/about-cancer/managing-care/finding-cancer-care
• National Cancer Institute – Surgical Pathology Reports https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet
• American Cancer Society – Seeking a Second Opinion https://www.cancer.org/cancer/making-treatment-decisions/seeking-a-second-opinion.html
• American Cancer Society – Managing Medical Records https://www.cancer.org/cancer/coping/managing-medical-records-and-insurance-receipts.html
• American Society of Clinical Oncology – Cancer Treatment and Survivorship Care Plans https://www.asco.org/practice-patients/patient-resources/asco-resources-patients-providers
• King’s College Hospital NHS Foundation Trust – Seeking a Second Opinion https://www.kch.nhs.uk/patients-and-visitors/help-and-support/seeking-a-second-opinion/